Literature DB >> 17268830

Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma.

Mikio Tezuka1, Keiji Hayashi, Kazunori Kubota, Sachiko Sekine, Yoichi Okada, Hiroyasu Ina, Tetsuya Irie.   

Abstract

We compared the growth rate of locally recurrent hepatocellular carcinoma (HCC) with that of primary HCC. After the first treatment by transcatheter arterial chemoembolization (TACE), 60 locally recurrent HCC nodules were reviewed. The tumor volume doubling time (DT) of locally recurrent HCC was significantly shorter than that of primary HCC. The 95% lower threshold value was 17.7 days. The 6-, 12-, and 36-month recurrence-free rates of the tumors having DTs more than 70 days after the second TACE (77.7%, 53.8%, and 40.4%) were significantly higher than those of the tumors having DTs less than 70 days (26.7%, 26.7%, and 17.8%). Locally recurrent HCCs cannot double in diameter in less than 53 days. In the case that an equivocal lesion smaller than the section collimation depicted during a contrast-enhanced computed tomography (CECT) screening cannot be ruled out as local recurrence, the next CECT screening should be performed 2 months later.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268830     DOI: 10.1007/s10620-006-9537-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  29 in total

1.  Computed tomography-guided transarterial chemoembolization as the initial therapy for hepatocellular carcinoma: experience of 75 cases in a single institute.

Authors:  Yoichi Okada; Hiroyasu Ina; Kazunori Kubota; Yoshiro Himeno; Toshihiko Wakita; Isamu Ohashi; Naoya Gomi; Tetsuo Yoshida; Sunao Mae; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

2.  Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography.

Authors:  Kazunori Kubota; Hiroyasu Ina; Yoichi Okada; Tetsuya Irie
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

3.  Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients.

Authors:  M Ebara; M Ohto; T Shinagawa; N Sugiura; K Kimura; S Matsutani; M Morita; H Saisho; Y Tsuchiya; K Okuda
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

4.  Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy.

Authors:  J Figueras; E Jaurrieta; C Valls; E Ramos; T Serrano; A Rafecas; J Fabregat; J Torras
Journal:  J Am Coll Surg       Date:  2000-05       Impact factor: 6.113

5.  Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients.

Authors:  M Ebara; R Hatano; H Fukuda; M Yoshikawa; N Sugiura; H Saisho
Journal:  Hepatogastroenterology       Date:  1998-08

6.  Recurrence of hepatocellular carcinoma after surgery.

Authors:  J Yamamoto; T Kosuge; T Takayama; K Shimada; S Yamasaki; H Ozaki; N Yamaguchi; M Makuuchi
Journal:  Br J Surg       Date:  1996-09       Impact factor: 6.939

7.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

8.  Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization.

Authors:  Jae Kyun Lee; Young-Hwa Chung; Byung-Cheol Song; Jung Woo Shin; Won-Beom Choi; Soo Hyun Yang; Hyun-Ki Yoon; Kyu-Bo Sung; Yung Sang Lee; Dong Jin Suh
Journal:  J Gastroenterol Hepatol       Date:  2002-01       Impact factor: 4.029

9.  CT evaluation of hepatic tumors: comparison of CT with arterial portography, CT with infusion hepatic arteriography, and simultaneous use of both techniques.

Authors:  T Irie; K Takeshita; Y Wada; S Kusano; S Terahata; S Tamai; K Hatsuse; H Aoki; Y Sugiura
Journal:  AJR Am J Roentgenol       Date:  1995-06       Impact factor: 3.959

Review 10.  Repeated liver resection for recurrent liver cancer.

Authors:  N Neeleman; R Andersson
Journal:  Br J Surg       Date:  1996-07       Impact factor: 6.939

View more
  17 in total

1.  Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model.

Authors:  Eun Ju Cho; Su Jong Yu; Kyungmin Kim; Heki Cho; Young Youn Cho; Yun Bin Lee; Jeong-Hoon Lee; Yoon Jun Kim; Hyewon Youn; Jung-Hwan Yoon
Journal:  J Bioenerg Biomembr       Date:  2019-02-12       Impact factor: 2.945

2.  Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization.

Authors:  Woo Sun Rou; Byung Seok Lee; Hee Seok Moon; Eaum Seok Lee; Seok Hyun Kim; Heon Young Lee
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

3.  Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis.

Authors:  Su-jong Yu; Jung-hwan Yoon; Jeong-hoon Lee; Sun-jung Myung; Eun-sun Jang; Min-sun Kwak; Eun-ju Cho; Ja-june Jang; Yoon-jun Kim; Hyo-suk Lee
Journal:  Acta Pharmacol Sin       Date:  2011-06-13       Impact factor: 6.150

4.  Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma.

Authors:  Terence P F Gade; Elizabeth Tucker; Michael S Nakazawa; Stephen J Hunt; Waihay Wong; Bryan Krock; Charles N Weber; Gregory J Nadolski; Timothy W I Clark; Michael C Soulen; Emma E Furth; Jeffrey D Winkler; Ravi K Amaravadi; M Celeste Simon
Journal:  Radiology       Date:  2017-03-02       Impact factor: 11.105

Review 5.  Advances in non-surgical management of primary liver cancer.

Authors:  Xiao Chen; Hai-Peng Liu; Mei Li; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

6.  Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition.

Authors:  Su Jong Yu; Jung-Hwan Yoon; Jong-In Yang; Eun Ju Cho; Min Sun Kwak; Eun Sun Jang; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Bioenerg Biomembr       Date:  2012-02-15       Impact factor: 2.945

7.  Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression.

Authors:  Chang-Hsien Liu; Ronald S Arellano; Raul N Uppot; Anthony E Samir; Debra A Gervais; Peter R Mueller
Journal:  Eur Radiol       Date:  2009-09-16       Impact factor: 5.315

Review 8.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

Review 9.  LI-RADS treatment response assessment of combination locoregional therapy for HCC.

Authors:  Marielia Gerena; Christopher Molvar; Mark Masciocchi; Sadhna Nandwana; Carl Sabottke; Bradley Spieler; Rishi Sharma; Leo Tsai; Ania Kielar
Journal:  Abdom Radiol (NY)       Date:  2021-06-13

10.  Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma.

Authors:  Yuri Cho; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Chung Yong Kim; Jung-Hwan Yoon
Journal:  Dig Dis Sci       Date:  2016-04-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.